Genprex

Monthly Archives: June 2018

Genprex Selects 4Clinics To Provide Clinical And Regulatory Support For Oncoprex Development Program

AUSTIN, Texas AND CAMBRIDGE, Mass., June 26, 2018 /PRNewswire/ — Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has selected 4Clinics Group Sprl to provide support for the clinical development of the Company’s lead drug candidate, Oncoprex™, for the treatment of non-small cell lung cancer (NSCLC)….

Read More